We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Replacement Knee System Conserves Bone and Ligament

By HospiMedica staff writers
Posted on 30 Jul 2007
An innovative knee system may give nearly 70% of all patients receiving a total knee replacement a more minimally invasive, bone and ligament preserving treatment alternative.

The Journey Deuce bi-compartmental knee system replaces the medial tibiofemoral compartment and patellofemoral compartment with a single femoral component. More...
The lateral tibiofemoral compartment is left untouched. The deuce implant retains both the anterior cruciate ligament (ACL) and the posterior cruciate ligament (PCL), allowing more normal kinematics throughout the range of motion (retention of the ACL and PCL has been shown to maintain patient proprioception). A range of six femoral and tibial sizes has been designed for optimum fit and to accommodate both men and women. The system is available in Oxinium (oxidized zirconium), a patented bearing surface that has been shown to reduce wear up to 85%, thereby potentially increasing the longevity of the implant. The Journey Deuce is a product of Smith & Nephew (Memphis, TN, USA).

"With the retention of the anterior and posterior cruciate ligaments, the Journey Deuce knee system addresses an unmet need in the market for the active, informed patient who may be concerned about potential reduced knee function and mobility with a total knee,” said Joseph DeVivo, president of Smith & Nephew orthopaedic reconstruction. "The Journey Deuce knee system provides a bone-conserving alternative to a total knee replacement, while allowing for earlier intervention and preserving all future surgery options for patients, including a total knee replacement.”

Oxinium is an advanced bearing product technology that transforms the surface of the implant to a ceramic, resulting in a material that incorporates the best features of ceramic and metal while avoiding the limitations associated with either material.


Related Links:
Smith & Nephew

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.